Pradaxa Lawsuits Mount, as Claims in Federal Multidistrict Litigation Exceed 2,000, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) December 27, 2013 -- Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to mount in the federal multidistrict litigation currently underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court documents, at least 2,017 lawsuits had been filed in the litigation as of December 27, 2013. All of the complaints pending in the proceeding accuse Boehringer Ingelheim of failing to provide adequate warnings regarding the serious risk of Pradaxa bleeding, especially the lack of an effective antidote for such an event. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“We hear from alleged victims of Pradaxa bleeding on a regular basis, so it is not surprising that the number of claims filed in this proceeding continues to climb. Our Firm expects that even more Pradaxa lawsuits will be filed in the coming year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered serious internal bleeding while using this medication.
Pradaxa Lawsuits
According to court documents, Pradaxa is a blood-thinning medication approved as a means of preventing strokes in people with atrial fibrillation. Upon its launch in 2010, Pradaxa was touted as a superior alternative to warfarin. However, lawsuits point out that while internal bleeding associated with decades-old warfarin can be stopped via the administration of vitamin k, there is no readily-available remedy for Pradaxa bleeding. Pradaxa lawsuits allege that due to the lack of an antidote, even a minor trauma can have serious health consequences for patients taking this medication.
In October, the Institute for Safe Medicine Practices (ISMP) reported that Pradaxa had been named in more than 3,200 adverse event reports made to the U.S. Food & Drug Administration (FDA) in 2012, including 582 fatalities. According to the ISMP analysis, Pradaxa led all other drugs in FDA adverse event reports that year. By contrast, warfarin was the subject of just 861 reports, including 56 deaths. *
The federal multidistrict litigation for Pradaxa lawsuits was established in August 2012. According to court documents, only 21 claims were transferred to the proceeding at that time. The litigation’s first bellwether trial is scheduled to begin in August 2014.
Alleged victims of Pradaxa bleeding may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury-related damages. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.pradaxalawsuithelp.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Pradaxa Lawsuit Information Center, http://www.pradaxalawsuithelp.com, +1 800-511-5092, [email protected]
Share this article